Premium
Ranolazine and late cardiac sodium current – a therapeutic target for angina, arrhythmia and more?
Author(s) -
Makielski Jonathan C,
Valdivia Carmen R
Publication year - 2006
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0706713
Subject(s) - ranolazine , medicine , angina , cardiology , long qt syndrome , cardiac arrhythmia , pharmacology , qt interval , atrial fibrillation , myocardial infarction
Ranolazine is a new antianginal drug approved for clinical use in the United States in January 2006. A study published in this same issue of the British Journal of Pharmacology characterizes ranolazine block of late sodium current caused by the long QT syndrome 3 mutations. This commentary discusses the implications of that study and the background and implications for block of late cardiac sodium current in general. British Journal of Pharmacology (2006) 148 , 4–6. doi: 10.1038/sj.bjp.0706713